Premier Biomedical, Inc. (BIEI) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Premier Biomedical, Inc. (BIEI) Healthcare & Pipeline Overview

Premier Biomedical, Inc. is a Knoxville-based research company established in 2010, specializing in the development and identification of innovative medical offerings. The firm primarily focuses on formulating and disseminating topical pain management solutions that incorporate hemp oil, operating within the biotechnology sector to address unmet medical needs.

What Is the Investment Thesis for BIEI?

Premier Biomedical, Inc. presents an investment thesis centered on its research-driven approach within the biotechnology sector, specifically targeting the topical pain management market with hemp oil solutions. The company's innovative focus on addressing unmet medical needs could represent a significant value driver if its product pipeline progresses successfully through clinical development and regulatory approval. With a market capitalization of $0.00B and a Beta of 0.74, the company is in an early, highly speculative stage, indicating potential for substantial upside if milestones are met, but also significant risk. Key catalysts include advancements in clinical trials, successful navigation of regulatory pathways for its hemp-based products, and securing future funding to sustain its research and development efforts. Investors must closely monitor the company's progress in these areas, as its OTC Other listing inherently carries risks associated with thinly traded securities and limited disclosure, making due diligence critical for assessing its long-term viability and potential for commercialization.

Based on FMP financials and quantitative analysis

BIEI Key Highlights

• Market Capitalization: $0.00B, reflecting its status as a micro-cap or pre-revenue stage company.
• Beta: 0.74, suggesting the stock has historically exhibited lower volatility compared to the broader market.
• Employee Count: Operates with a lean team of 4 employees, indicating a focused research and development structure.
• Dividend Policy: Does not currently distribute dividends to shareholders.
• Operational Focus: Primarily engaged in the research, genesis, and identification of innovative medical offerings, with a specific emphasis on topical pain management solutions utilizing hemp oil.

Who Are BIEI's Competitors?

BIEI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are BIEI's Key Strengths?

• Focused research and development efforts in the growing topical pain management market.
• Innovative approach to medical offerings, particularly utilizing hemp oil.
• Lean operational structure with a small, dedicated team of 4 employees.
• Addresses unmet medical needs within the pain management sector.

What Are BIEI's Weaknesses?

• Micro-cap status with a $0.00B market capitalization, indicating early-stage and high risk.
• OTC Other listing, implying higher inherent risks, limited liquidity, and reduced transparency.
• Limited employee base (4 employees) which may constrain extensive R&D and commercialization efforts.
• Significant reliance on securing future funding to advance its research pipeline and operations.

What Could Drive BIEI Stock Higher?

• Progress in research and development efforts for its innovative topical pain management solutions.
• Potential initiation or advancement of clinical trials for its medical offerings, providing data on efficacy and safety.
• Pursuit and achievement of regulatory approvals for its hemp oil-based products, opening pathways for commercialization.
• Securing additional funding through private placements, grants, or strategic partnerships to support its research pipeline and operational needs.
• Continued development of innovative medical offerings aimed at addressing specific unmet needs within the healthcare sector.

What Are the Key Risks for BIEI?

• Weak fundamentals — a Piotroski F-Score of 0/9 flags soft profitability, leverage or efficiency.
• Inherent risks associated with thinly traded securities and speculative ventures typical of the OTC Other market.
• Failure to secure sufficient future funding necessary for sustained research, development, and potential commercialization efforts.
• Negative outcomes, delays, or outright failures in clinical trials for its medical technologies, impacting product viability.
• Inability to obtain necessary regulatory approvals for product commercialization, preventing market entry.
• Intense competition within the biotechnology and pain management sectors from larger, more established companies.

What Are the Growth Opportunities for BIEI?

• Growth opportunity 1: **Expansion in the Topical Pain Management Market**: The global market for pain management is experiencing significant growth, driven by an aging population and a societal shift towards non-opioid and localized treatment options. Premier Biomedical's focus on topical pain management solutions, particularly those incorporating hemp oil, positions it to potentially capitalize on this expanding demand. As consumer and medical acceptance of hemp-derived products increases, the company could see a substantial market for its innovative formulations, especially if they demonstrate superior efficacy and safety profiles compared to existing alternatives. This market trend offers a long-term growth runway.
• Growth opportunity 2: **Advancements in Hemp Oil Formulation and Delivery**: Ongoing research into optimizing the bioavailability, stability, and efficacy of hemp oil in topical applications represents a significant growth opportunity. Premier Biomedical's dedicated research efforts in this area could lead to the development of proprietary, advanced formulations that offer enhanced therapeutic benefits. Such advancements could result in stronger intellectual property, superior product performance, and a competitive edge, allowing the company to capture a larger share of the specialized pain relief market as scientific understanding and technological capabilities evolve over the next 3-5 years.
• Growth opportunity 3: **Successful Regulatory Pathway Navigation**: Achieving regulatory approvals for its topical pain management solutions is a critical growth catalyst. Successful navigation of regulatory processes, such as securing FDA clearance or similar international approvals, would validate the safety and efficacy of its products. This would transition the company from a pure R&D entity to one capable of commercializing its innovations, unlocking significant market access and revenue potential. The timeline for such approvals is typically multi-year, but each successful step would de-risk the investment and open new market segments.
• Growth opportunity 4: **Strategic Partnerships and Licensing Agreements**: Given its lean operational structure and research focus, forming strategic partnerships with larger pharmaceutical companies, consumer health brands, or distribution networks presents a substantial growth opportunity. These collaborations could provide Premier Biomedical with essential capital, accelerate product development, and offer immediate access to broader distribution channels and established marketing infrastructure. Licensing its proprietary formulations or technologies could generate revenue streams without the need for extensive internal commercialization efforts, significantly expanding its market reach within a 2-4 year timeframe.
• Growth opportunity 5: **Diversification of Medical Offerings**: While currently focused on topical pain management, Premier Biomedical's broader mandate of 'genesis and identification of innovative medical offerings' suggests potential for pipeline diversification. Leveraging its research capabilities, the company could explore other therapeutic areas, diagnostic tools, or medical technologies beyond its current scope. This strategic expansion could open new market segments, reduce reliance on a single product category, and provide multiple avenues for growth, potentially creating new revenue streams over a 5-10 year horizon as new research initiatives mature.

What Opportunities Does BIEI Have?

• Expanding market for non-opioid and hemp-based pain solutions globally.
• Potential for strategic partnerships or licensing agreements to accelerate development and market reach.
• Successful navigation of regulatory pathways for product commercialization, unlocking significant revenue potential.
• Diversification into other therapeutic areas leveraging its core R&D capabilities and expertise.

What Threats Does BIEI Face?

• Intense competition from established pharmaceutical and biotechnology companies with greater resources.
• Significant regulatory hurdles and potential adverse changes in legislation concerning hemp-derived products.
• Failure to secure adequate funding, which could halt research, development, and commercialization efforts.
• Risk of clinical trial failures or lack of demonstrated efficacy in product development, leading to project termination.

What Are BIEI's Competitive Advantages?

• Proprietary research and development processes for identifying and formulating innovative medical offerings.
• Specialized focus on hemp oil-based topical pain management solutions, potentially leading to unique formulations.
• Potential for intellectual property protection (patents) on its specific product formulations or delivery methods.
• Early-stage positioning in niche areas of hemp-derived therapeutics, allowing for focused expertise development.

What Does BIEI Do?

Premier Biomedical, Inc. was founded on May 10, 2010, by Mitchell S. Felder, establishing its central operations in Knoxville, Tennessee. The company functions as a research-intensive entity, actively engaged in both the genesis and identification of innovative medical offerings. Its core focus is directed toward formulating and disseminating topical pain management solutions, specifically those that integrate hemp oil. This specialization positions Premier Biomedical within the broader biotechnology sector, where it aims to develop and commercialize medical technologies. The company's operational pipeline includes ongoing research into various therapies and diagnostics, reflecting its commitment to addressing unmet medical needs through scientific innovation. As a lean organization with 4 employees, Premier Biomedical emphasizes a focused approach to product development, aiming to bring novel solutions to market. Its strategic intent is to leverage research and development capabilities to create value in the healthcare landscape, particularly within the growing segment of alternative pain management. The company's journey since its inception has been characterized by a dedication to exploring new frontiers in medical science, with a clear emphasis on its hemp oil-based topical solutions as a primary commercialization pathway.

What Products and Services Does BIEI Offer?

• Conducts research for innovative medical offerings.
• Identifies new medical solutions and technologies.
• Formulates topical pain management solutions.
• Disseminates specialized topical pain management products.
• Incorporates hemp oil as a key ingredient in its pain management formulations.
• Operates within the biotechnology sector, focusing on medical technology development.
• Aims to address unmet medical needs through its research and product pipeline.

How Does BIEI Make Money?

• Engages in the research and development of proprietary medical technologies and formulations.
• Seeks to commercialize its developed topical pain management solutions, particularly those utilizing hemp oil.
• Focuses on securing necessary regulatory approvals to bring its innovative products to market.
• Potentially generates revenue through the sale of its medical products or by licensing its intellectual property to other entities.

What Industry Does BIEI Operate In?

Premier Biomedical, Inc. operates within the dynamic Healthcare sector, specifically positioned in the Medical - Pharmaceuticals industry with a focus on biotechnology. The company's niche in topical pain management, particularly with hemp oil, places it within a rapidly evolving market segment driven by increasing demand for non-opioid pain solutions and growing acceptance of cannabis-derived therapeutics. The global pain management market is substantial and continues to expand, fueled by an aging population and a rise in chronic conditions. BIEI's innovative approach aims to address unmet medical needs, differentiating itself from larger pharmaceutical companies that may focus on traditional drug development. The competitive landscape includes established pharmaceutical giants, specialized biotech firms, and numerous smaller companies exploring cannabinoid-based therapies. Premier Biomedical's success hinges on its ability to carve out a distinct position through effective R&D and successful commercialization in this competitive and highly regulated environment.

Who Are BIEI's Key Customers?

• Currently, its primary 'customer' is its internal research and development pipeline.
• Future potential customers include patients seeking effective topical pain relief.
• Healthcare providers, such as physicians and specialists, who prescribe or recommend pain management solutions.
• Pharmacies, retail outlets, and online platforms that distribute healthcare products.

Net buyingInsider Activity

The most recent 12 insider filings for Premier Biomedical, Inc. break down as 0 sales and 12 purchases. On net that is roughly 20.7M shares acquired (about $18K) — insiders putting money in tends to read as conviction.

BIEI Valuation & Market Position

Relative to its peer group, BIEI's quantitative score of 46/100 is roughly in line with the peer average of 52/100.

ROE 3%Key Financial Metrics

Return on equity for Premier Biomedical, Inc. stands at 3.4%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -2.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -7.0%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 0/9Financial Health

Premier Biomedical, Inc.'s Piotroski F-Score is 0/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

Company Profile

Premier Biomedical, Inc. operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Knoxville, US. The company is led by CEO David Caplan. BIEI has traded publicly since 2012.

BIEI Financials

BIEI Latest News

BIEI Analyst Consensus

BIEI MoonshotScore

Premier Biomedical, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources